Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the 2024 Annual Meeting of the American Society of Retina Specialists (ASRS) held July 17-20, in Stockholm, Sweden.

Dr. Abbey presented on behalf of the CALM registry study investigators and supporting clinical sites. The study’s purpose is to analyze Phase IV real-world outcomes among patients with chronic non-infectious uveitis of the posterior segment (NIU-PS) who are receiving the intravitreal 0.18 mg fluocinolone acetonide implant (FAi). Optical coherence tomography (OCT) is a non-invasive diagnostic imaging test that allows retina specialists to clearly see the retina and carefully map and measure the thickness of its individual layers.

“Evidence from this real-world registry builds on controlled clinical studies,” explained Dr. Abbey. “The 0.18 mg FAi provided long-term improvements in inflammatory flares with no new safety signals. Overall, three-year post IVT FAi patients experienced a substantial reduction in uveitis flares, improved OCT findings and stable vision.”

At ASRS 2024, Dr. Abbey also earned a Senior Honor Award in recognition of his time and contributions to the scientific programs of the organization’s annual meetings. He joined Texas Retina in 2015 and serves as director of clinical research for Dallas. Dr. Abbey cares for patients in the Dallas Main and Rockwall offices.

Texas Retina’s Rajiv Anand, MD, and Robert C. Wang, MD, also presented at the ASRS 2024 Annual Meeting. 

About the American Society of Retina Specialists (ASRS)
ASRS is the largest organization of retinal specialists in the world, representing over 3,000 physicians in all 50 US states, the District of Columbia, Puerto Rico, and 63 countries. The Society serves as a national advocate and primary source of clinical and scientific information and education for its members.